Jiangsu Changyou Environmental Protection Technology
301557
Hefei conver Holding
603409
LIERDA
832149
4
SHENGNAN TECHNOLOGY
837006
5
CHK
831167
CN Stock MarketDetailed Quotes
002252 Shanghai RAAS Blood Products
- 6.86
- +0.08+1.18%
Not Open Mar 4 15:00 CST
45.54BMarket Cap24.86P/E (TTM)
6.87High6.80Low318.70KlotVolume6.81Open6.78Pre Close218.00MTurnover0.48%Turnover Ratio25.60P/E (Static)6.64BShares8.6852wk High1.46P/B45.51BFloat Cap6.3852wk Low7.46Limit Up6.63BShs Float26.43Historical High6.10Limit Down1.03%Amplitude0.39Historical Low0.07Dividend TTM6.84Avg Price120.63KlotAsk0.98%Div YieldTTM100Lot Size192.40KlotBid
Shanghai RAAS Blood Products Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 6.39%6.31B | 9.02%4.25B | -0.33%2.06B | 21.27%7.96B | 19.87%5.94B | 18.43%3.9B | 22.40%2.06B | 53.16%6.57B | 62.53%4.95B | 87.59%3.29B |
| Operating revenue | 6.39%6.31B | 9.02%4.25B | -0.33%2.06B | 21.27%7.96B | 19.87%5.94B | 18.43%3.9B | 22.40%2.06B | 53.16%6.57B | 62.53%4.95B | 87.59%3.29B |
| Other operating revenue | ---- | 9.42%956.97K | ---- | 19.10%1.57M | ---- | 15.78%874.58K | ---- | -56.07%1.32M | ---- | 39.20%755.37K |
| Total operating cost | 9.51%4.48B | 13.12%3.04B | 6.02%1.44B | 22.98%5.55B | 22.14%4.09B | 21.03%2.69B | 24.52%1.36B | 62.93%4.51B | 76.47%3.35B | 111.76%2.22B |
| Operating cost | 8.74%3.75B | 12.20%2.51B | 6.94%1.24B | 28.57%4.72B | 26.88%3.45B | 22.87%2.24B | 26.81%1.16B | 77.56%3.67B | 93.00%2.72B | 142.65%1.82B |
| Operating tax surcharges | 43.97%40.78M | 51.33%30.03M | 42.43%12.36M | 14.89%37.69M | 32.25%28.33M | 35.13%19.84M | 21.46%8.68M | 42.32%32.81M | 35.51%21.42M | 42.97%14.68M |
| Operating expense | -11.88%250.65M | 0.70%196.01M | -21.12%66.68M | -10.53%333.76M | 0.18%284.44M | 10.04%194.65M | -2.99%84.54M | 21.85%373.03M | 25.82%283.94M | 36.19%176.88M |
| Administration expense | 25.67%315.18M | 27.31%208.3M | -1.01%95.59M | 13.66%378.98M | 6.34%250.81M | 3.72%163.62M | 40.10%96.57M | 7.38%333.45M | 12.90%235.86M | 13.75%157.74M |
| Financial expense | -26.92%-61.9M | 31.41%-9.65M | 33.38%-24.61M | -121.98%-91.58M | -511.51%-48.77M | -5.29%-14.07M | -75.34%-36.95M | 36.97%-41.26M | 78.02%-7.98M | 44.77%-13.36M |
| -Interest expense (Financial expense) | -27.38%61.4K | -24.60%45.79K | -33.61%21.59K | -54.50%119.75K | -62.02%84.54K | -67.94%60.73K | -75.39%32.51K | -44.25%263.18K | -35.14%222.62K | 2.85%189.4K |
| -Interest Income (Financial expense) | 11.26%-90.33M | 9.76%-61.04M | -4.98%-32.95M | -37.71%-135.38M | -53.55%-101.79M | -70.28%-67.64M | -71.34%-31.38M | -77.38%-98.31M | -120.08%-66.29M | -51.85%-39.72M |
| Research and development | 44.04%190.78M | 22.05%106.03M | 8.84%50.09M | 19.24%173.74M | 29.74%132.45M | 35.24%86.87M | 33.77%46.02M | 12.93%145.71M | 31.32%102.09M | 46.03%64.23M |
| Credit Impairment Loss | -2,780.55%-32.09M | -412.23%-20.99M | -125.07%-2.66M | 131.87%5.22M | 105.70%1.2M | 141.20%6.72M | 186.17%10.6M | -251.24%-16.38M | -592.92%-21.01M | -407.36%-16.32M |
| Asset Impairment Loss | -45.13%-13.51M | -345.67%-11.04M | 157.10%1.22M | 88.45%-24M | -51.11%-9.31M | -275.35%-2.48M | -59.24%-2.13M | 44.01%-207.72M | -18.28%-6.16M | 193.94%1.41M |
| Other net revenue | 56.80%430.89M | 36.79%341.25M | 116.78%301.21M | -185.55%-190.72M | -8.88%274.8M | 27.73%249.48M | 166.32%138.94M | 527.27%222.92M | -31.76%301.58M | -39.26%195.31M |
| Fair value change income | ---- | ---- | --0 | -319.57%-40.36M | -227.78%-23.58M | 916.67%39.16M | 122.13%10.79M | 142.99%18.38M | 80.22%-7.19M | 87.50%-4.8M |
| Invest income | 47.34%439.92M | 68.58%339.34M | 129.31%268.7M | -137.30%-153.82M | -7.74%298.58M | -2.56%201.3M | 6.05%117.18M | 0.42%412.39M | -29.00%323.64M | -38.33%206.58M |
| -Including: Investment income associates | -11.40%261M | -18.69%160.42M | -23.38%89.78M | -138.27%-157.82M | -8.98%294.58M | -4.49%197.3M | 6.05%117.18M | 1.41%412.39M | -28.37%323.64M | -37.59%206.58M |
| Asset deal income | -636,116.12%-1.6M | -9,682,141.35%-1.16M | -1,450.67%-1.15M | -105.50%-12.49K | -99.67%252.18 | -99.97%12.02 | 150.79%85.08K | 116.80%227.19K | 108.33%76.79K | 104.15%34.9K |
| Other revenue | 382.81%38.18M | 635.91%35.11M | 1,345.89%35.1M | 38.91%22.26M | -35.29%7.91M | -43.18%4.77M | -39.82%2.43M | -44.99%16.02M | -49.76%12.22M | -61.81%8.4M |
| Operating profit | 6.88%2.26B | 6.20%1.55B | 8.75%915.96M | -2.35%2.23B | 11.30%2.12B | 15.30%1.46B | 30.44%842.27M | 46.60%2.28B | 19.64%1.9B | 23.16%1.26B |
| Add:Non operating Income | -14.93%461.44K | 17.00%179.52K | 91.24%105.48K | 712.15%2.42M | 47.21%542.41K | -39.98%153.43K | 7.51%55.16K | -28.82%297.57K | 2.01%368.46K | -10.78%255.65K |
| Less:Non operating expense | 1,006.32%98.05M | 2,153.26%79.44M | 940.15%12.96M | 316.59%23.66M | 324.35%8.86M | 152.95%3.53M | 134.39%1.25M | -64.41%5.68M | -86.25%2.09M | -52.12%1.39M |
| Total profit | 2.67%2.16B | 0.99%1.47B | 7.37%903.11M | -3.06%2.2B | 10.96%2.11B | 15.14%1.46B | 30.36%841.08M | 47.73%2.27B | 20.65%1.9B | 23.36%1.26B |
| Less:Income tax cost | 1.08%325.15M | 5.18%228.49M | 18.90%146.03M | 6.50%426.65M | 7.38%321.68M | 5.48%217.25M | 23.77%122.82M | 60.19%400.61M | 65.31%299.58M | 77.47%205.97M |
| Net profit | 2.96%1.84B | 0.26%1.24B | 5.40%757.08M | -5.10%1.78B | 11.63%1.79B | 17.02%1.24B | 31.55%718.27M | 45.31%1.87B | 14.84%1.6B | 16.45%1.06B |
| Net profit from continuing operation | 2.96%1.84B | 0.26%1.24B | 5.40%757.08M | -5.10%1.78B | 11.63%1.79B | 17.02%1.24B | 31.55%718.27M | 45.31%1.87B | 14.84%1.6B | 16.45%1.06B |
| Less:Minority Profit | 135.59%706.99K | 123.09%266.98K | 186.54%261.39K | 71.18%-2.04M | 53.35%-1.99M | 64.30%-1.16M | 85.24%-302.04K | -27.50%-7.09M | -26.04%-4.26M | -59.95%-3.24M |
| Net profit of parent company owners | 2.81%1.84B | 0.15%1.24B | 5.32%756.82M | -5.35%1.78B | 11.46%1.79B | 16.77%1.24B | 31.12%718.57M | 45.24%1.88B | 14.87%1.6B | 16.55%1.06B |
| Earning per share | ||||||||||
| Basic earning per share | 4.14%0.277 | 1.63%0.187 | 6.54%0.114 | -3.57%0.27 | 11.76%0.266 | 17.20%0.184 | 32.10%0.107 | 47.37%0.28 | 14.98%0.238 | 16.30%0.157 |
| Diluted earning per share | 4.14%0.277 | 1.63%0.187 | 6.54%0.114 | -3.57%0.27 | 11.76%0.266 | 17.20%0.184 | 32.10%0.107 | 47.37%0.28 | 14.98%0.238 | 16.30%0.157 |
| Other composite income | -133.57%-153.41M | -87.16%72.94M | 125.21%47.95M | -77.83%271.39M | -68.88%456.98M | -17.11%568.04M | -184.80%-190.19M | 450.35%1.22B | 1,718.65%1.47B | 626.42%685.31M |
| Other composite income of parent company owners | -133.57%-153.41M | -87.16%72.94M | 125.21%47.95M | -77.83%271.39M | -68.88%456.98M | -17.11%568.04M | -184.80%-190.19M | 450.35%1.22B | 1,718.65%1.47B | 626.42%685.31M |
| Total composite income | -24.86%1.69B | -27.24%1.31B | 52.45%805.02M | -33.84%2.05B | -26.91%2.24B | 3.60%1.81B | 10.20%528.07M | 229.61%3.1B | 135.64%3.07B | 123.99%1.74B |
| Total composite income of parent company owners | -24.96%1.68B | -27.30%1.31B | 52.31%804.76M | -33.93%2.05B | -26.95%2.24B | 3.47%1.81B | 9.79%528.37M | 228.42%3.1B | 135.36%3.07B | 123.82%1.75B |
| Total composite income of minority owners | 135.59%706.99K | 123.09%266.98K | 186.54%261.39K | 71.18%-2.04M | 53.35%-1.99M | 64.30%-1.16M | 85.24%-302.04K | -27.50%-7.09M | -26.04%-4.26M | -59.95%-3.24M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.